Core Insights - The article highlights two undervalued dividend stocks, Zoetis and Nomad Foods, as attractive investment opportunities in a market characterized by high valuations for growth stocks [1][2]. Zoetis - Zoetis is a global leader in animal healthcare, generating over $100 million annually from 17 blockbuster products [5]. - The company has seen its market value decline by 50% since 2022, despite its leading position in the market [6]. - Currently trading at 20 times earnings, Zoetis is at its lowest valuation ever, making it appealing for dividend investors [9]. - The company maintains a strong innovation pipeline, with new monoclonal antibody drugs aimed at treating osteoarthritis in pets [10]. - Zoetis' livestock unit provides stability, as demand for protein is expected to rise, ensuring continued need for its products [11]. - The company has a return on invested capital (ROIC) of 22%, indicating strong profitability and cash returns to shareholders [12]. - Over the last decade, Zoetis has increased its dividend by 19% annually, with a current yield of 1.7% [13]. Nomad Foods - Nomad Foods is the leading frozen foods provider in Europe, particularly in the protein and vegetable categories [14]. - The stock has dropped 62% from its all-time high in 2021, trading at a low enterprise value to EBITDA ratio of 7 [15]. - Recent sales and adjusted earnings declined by 2% and 11% respectively, attributed to unusual weather affecting the frozen food market [17]. - The company is focusing on healthier food options, with new chicken offerings and protein bowls seeing a 34% increase in sales [19]. - Management prioritizes share repurchases as a key use of cash flow, having reduced share count by 4% annually over the last five years [21]. - Nomad has initiated a new dividend yielding 5.7%, utilizing only 46% of its net income [21]. - The CFO's personal investment of $1 million in Nomad shares signals confidence in the company's undervaluation [23].

lots of focus on uh Mr. . Mr. . uh Kennedy and his views on on vaccines.Those views do they provide any long-term risk to a business like Fiser. >> Not long term because we are not going to go back to past times, right. Vaccines have saved the world and we'll continue doing that in the long term is the most cost effective uh medical healthcare intervention.Now I interacted a lot with Bobby Kennedy and the secretary. Clearly that was not going to be my choice for it's a secretary but it's not my choice. It i ...

Core Viewpoint - The article emphasizes the need for reliable monthly passive income for retirees, especially in light of a modest 2.8% increase in Social Security benefits that does not keep pace with a 3.0% inflation rate [2][3]. Group 1: Dividend-Paying Stocks - Dividend-paying stocks are highlighted as a viable option for generating reliable monthly passive income, as they distribute a portion of the company's earnings regularly, typically every three months [3]. - The article identifies four companies with a strong history of paying and increasing dividends, making them dependable sources of income throughout the year [3]. Group 2: Featured Company - Johnson & Johnson - Johnson & Johnson is presented as a key example of a company that provides reliable dividends, operating in the healthcare sector with a diverse product range including baby shampoo, medical devices, and vaccines [4][5].

Diamond Hill Capital, an investment management company, released its “Select Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets continued their YTD rally in the third quarter, with the Russell 3000 Index surging 8%. At the same time, the portfolio underperformed the Russell 3000 Index, returning 4.98%. To get an idea of the fund’s best choices for 2025, check out its top 5 positions. In its third-quarter 2025 investor letter, Diamond Hill Select Fund highlighted ...

Core Insights - Analysts identify nine S&P 500 stocks that have declined 30% or more this year, including Moderna and Kenvue, which are expected to rally by 30% or more in the next 12 months [1][6]. Group 1: Market Performance - The S&P 500 has increased by 35% since its year-to-date low on April 8, 2025, and has risen over 92% since the bull market began on October 12, 2022, excluding dividends [2]. - Analysts are searching for stocks that have not yet fully participated in the current market rally [2]. Group 2: Company-Specific Analysis - Moderna's stock has dropped nearly 40% this year, with an expected earnings per share (EPS) decline of 4% [3]. - Despite the negative sentiment, analysts project a 59% upside for Moderna, targeting a price of 40.30 in 12 months [4]. - Kenvue's stock is down 32% this year, but analysts anticipate an 8% EPS increase in 2026, with a target price of 20.37, representing a 40.4% gain [4]. Group 3: Promising Stocks - The following "left out" S&P 500 stocks are expected to recover significantly: - Moderna (MRNA): YTD change -39.0%, 12-month upside 59.0% [6] - Alexandria Real Estate Equities (ARE): YTD change -35.5%, 12-month upside 52.6% [6] - GoDaddy (GDDY): YTD change -33.7%, 12-month upside 44.4% [6] - Kenvue (KVUE): YTD change -32.0%, 12-month upside 40.4% [6] - Fiserv (FI): YTD change -38.6%, 12-month upside 34.7% [6] - The Trade Desk (TTD): YTD change -56.0%, 12-month upside 34.6% [6] - Align Technology (ALGN): YTD change -36.1%, 12-month upside 31.5% [6] - Chipotle Mexican Grill (CMG): YTD change -33.2%, 12-month upside 31.4% [6] - Oneok (OKE): YTD change -31.2%, 12-month upside 31.3% [6]

Core Insights - Merck has commenced the construction of a new pharmaceutical manufacturing facility in Elkton, Virginia, as part of a $70 billion investment strategy in the U.S. [1][6] - The facility is expected to create 500 full-time jobs and approximately 8,000 construction jobs during its development [1][10] - This investment aligns with the U.S. administration's focus on domestic pharmaceutical production and reducing reliance on foreign manufacturing [2][6] Investment and Economic Impact - The new plant will enhance U.S. production capabilities for vaccines and critical medicines, including active pharmaceutical ingredients and small-molecule manufacturing [5] - Merck's expansion is projected to create over 48,000 construction-related jobs by 2029, with most construction expected to be completed by 2028 [10] - The Elkton facility marks Merck's fourth major U.S. manufacturing project initiated this year, alongside projects in Delaware, North Carolina, and Kansas [9] Strategic Alignment with Government Policy - Merck's leadership emphasizes collaboration with the U.S. administration to maintain the country's position as a leader in pharmaceutical innovation [3][11] - The announcement coincides with the White House's renewed emphasis on "Made in America" initiatives for pharmaceuticals [6] - Virginia's Governor has recognized the investment as a significant advancement for the state's life-sciences sector, reinforcing its status in advanced manufacturing and healthcare innovation [12]

Core Insights - The company reported a consolidated revenue of €1,102.4 million for the first half of 2025, reflecting a growth of +5.8% overall and +9.2% at constant exchange rates [1][6] - The growth in revenue is driven by the companion animal segment, which increased by +11.3%, and the farm animal segment, which grew by +6.1% [1][9] - The company has upgraded its full-year revenue guidance, now expecting growth between 5.5% and 7.5% at constant rates and scope [4][10] Revenue Performance - The third-quarter consolidated revenue reached €364.1 million, showing a strong growth of +12.5% at constant exchange rates and scope compared to the same period in 2024 [3] - Revenue growth in Europe was +6.1%, primarily driven by the companion animal segment, which grew by +9.2% [3][7] - North America experienced exceptional growth of +48.5% at constant exchange rates, largely due to a restocking effect on dental products [3][8] Regional Analysis - Latin America recorded strong growth of +11.1%, supported by both companion animals (+14.2%) and farm animals (+17.0%) [3][8] - The IMEA zone (India, Middle East, and Africa) showed sustained growth of +9.7%, predominantly in the farm animal segment [3][5] - East Asia experienced growth of +6.2%, driven by Japan, while China faced a decline of -2.6% due to challenges in the farm animal segment [5][8] Product Segment Performance - The companion animal business grew by +11.3%, driven by strong sales in dental, dermatology, petfood, and specialty products [9] - The farm animal segment showed growth of +6.1%, mainly from the ruminant segment with vaccines and nutritional products [9] - The integration of the acquired company Sasaeah contributed +1.4 percentage points to overall growth [6][10] Financial Outlook - The adjusted recurring operating income is expected to be around 16% for the year [4][10] - The company anticipates a moderate impact from potential increases in customs tariffs in the United States, with an estimated direct impact of around US$4 million for the full year [11][12] - Cash position is expected to improve by approximately €80 million in 2025, excluding any potential acquisitions [10]

Trump has now targeted aluminum in vaccines. Here's what we know about its safety. https://t.co/UHainG63I8 ...

Core Viewpoint - Merck (MRK) stock is highlighted for its monopoly-like high margins available at a discounted price, making it an attractive investment opportunity [1] Financial Performance - Revenue growth for Merck is reported at 1.8% for the last twelve months (LTM) and an average of 3.7% over the last three years [8] - Recent profitability metrics include approximately 29.1% operating cash flow margin and 31.2% operating margin for LTM [8] - Long-term profitability averages show about 27.2% operating cash flow margin and 22.6% operating margin over the last three years [8] - The stock is currently offered at a price-to-sales (P/S) multiple of 3.5, representing a 22% discount compared to one year ago [8] Investment Strategy - The Trefis High Quality Portfolio, which includes Merck, has a record of outperforming benchmark indices, including the S&P 500, S&P mid-cap, and Russell 2000 [11] - The selection process for stocks focuses on those with market capitalizations over $10 billion, high cash flow from operations margins, and those that have significantly decreased in value over the past year [6] Market Dynamics - The average 12-month forward returns for selected stocks are close to 19%, with a win rate of around 72% for positive returns [9]

Merck & Co., Inc. (NYSE:MRK) is one of the Best and Cheap Stocks to Buy Right Now. On September 30, Courtney Breen from Bernstein reiterated a Hold rating on Merck & Co., Inc. (NYSE:MRK) without disclosing any price target. Merck & Co., Inc. (NYSE:MRK) is set to announce its fiscal third quarter results on October 30. The company posted mixed results during its second quarter of 2025. The company topped Wall Street estimates with an EPS of $2.13, ahead of the consensus by $0.10. However, the revenue of $1 ...